natgillin/translations-raw huggingface dataset:
A composition according to claim 8, which comprises a further herbicide in addition to the compound of formula I. 
Sastav prema zahtjevu 21, naznačen time, da sadrži daljnje herbicide kao dodatak uz spoj formule I.
The mixture turned homogeneous and was stirred at ambient temperature for 1h. 
Smjesa postane homogena i miješa se na sobnoj temperaturi kroz 1 sat.
Water Content of Alkaloid (nicotine) containing Lozenges with Phosphate Buffer stored at 25° C./60% RH. 
Tabela Sa Količina vode tableta koje sadrže alkaloid (nikotin) sa fosfatnim puferom čuvane na 252C/60% relativne vlažnosti
The method of claim 2, wherein the effective amount of the fusion protein is administered in the form of a composition. 
Terapijski učinkovita količina farmaceutskog sastava prema bilo kojem od prethodnih zahtjeva 1 do 8 za uporabu u liječenju karcinoma kod pacijenata.
The composition of claim 14, wherein the amount of the alcohol ranges from about 1.0 to about 9.0, from about 2.0 to about 5.0, or from about 2.0 to about 4.0 molar equivalents per molar equivalent of trichloroisocyanuric acid. 
Postupak prema zahtjevu 1, naznačen time da je količina agensa za aciliranje u rasponu od oko 1 do oko 15, od oko 1 do oko 10 ili od oko 2 do oko 7 molarnih ekvivalenata po molarnom ekvivalentu spoja formule (II).
These auxiliary agents are dissolved or disperged either individually or together in water used for the pelletization, and added to the premix to be pelletized in the beginning of the pelletization procedure. 
Ove pomoćne tvari otapaju se ih raspršuju ili pojedinačno ili zajedno, u vodi koja se koristi za granuliranje, pa se dodaju prethodno načinjenoj smjesi koju treba granulirati i to na početku postupka granuliranja.
The vaccine composition of claim 9 wherein the viral vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, a herpesvirus vector, a lentivirus vector, a poxvirus vector and a retrovirus vector. 
Pripravak cjepiva u skladu s patentnim zahtjevom 9, naznačen time što se virusni vektor bira iz skupine koju čine adenovirusni vektor, adenoasocirani virusni vektor, herpesvirusni vektor, lentivirusni vektor, poksvirusni vektor i retrovirusni vektor.
1, a data transmission device 1 in accordance with the invention comprises a first and a second circuit section 1 a and 1 b galvanically isolated from each other and operating in parallel with and independently of each other. 
U odnosu na Sliku 1, naprava 1 za prijenos podataka u skladu s izumom sadrži prvu i drugu sekciju komunikacijskih krugova 1a 1 Ib galvanski izoliranu jednu od druge 1 koje rade paralelno 1 nezavisno jedna od druge.
The composition of claim 1, wherein the protein is a collagen, elastin, keratin, fibronectin, actin, myosin, laminin, a peptide or a blend of those proteins or peptides, hydrolyzed, chemically modified, fibrillated or not. 
Sastav prema zahtjevu 1, pri čemu je spomenuti protem kolagen, elastm, keratin, fibronektin, aktin, miozin, laminin, peptid ili mješavina spomenutih proteina ili peptida, hidroliziranih, kemijski modificiranih, fibriliranih 1li ne.
The propeller arrangement according to claim 1, characterised in that the diameter of the circular path of the at least one rotor fin is less than 75% of the diameter of the propeller. The propeller arrangement according to claim 2, characterised in that the diameter of the circular path of the at least one rotor fin is less than 55% of the diameter of the propeller. 
Sklop propelera prema zahtjevu 1, naznačen time da promjer (31) kružne staze barem jedne lopatice rotora (30) iznosi manje od 75%, poželjno manje od 55%, naročito poželjno manje od 35%, najpoželjnije manje od 25% promjera (16) propelera (10).
FIG. 18 shows an IR spectrum of a sample of a blend of compound of formula (I) in solid crystalline anhydrous form (micronized), Lactohale200® and magnesium stearate. 
Spoj prema zahtjevu 1, naznačen time da spoj s formulom (1) u krutom kristalnom obliku ima uzorak difrakcije X-zraka na prahu uglavnom kako je prikazano na slici 2.
A compound of any one of claims 1 to 9 or a salt thereof for use as a medicament, for use as an antimicrobial agent, or for use in the prevention or treatment of a bacterial infection. 
Spoj prema bilo kojem od zahtjeva 1 do 9, ili njegova sol, naznačen/a time, da se upotrebljava kao lijek, te time, da se upotrebljava kao antimikrobno sredstvo, ili time, da se upotrebljava u prevenciji ili liječenju bakterijske 20
reacting the above compound of formula IIb with 2-bromo-4-fluorophenol to give a compound of formula IIIb in the form of diastereoisomeric mixture (R,S+S,S) 
To m) reakciju gore navedenog spoja formule IIb sa 2-bromo-4-fluorofenolom, da bi dobio spoj formule IIIb u obliku dijasteroizomerne smjese (R, S+8, S)
The method of claim 14 comprising administering a pharmaceutical composition according to any of claims 1-13. The method of claim 14 or 15 further comprising administering an effective amount of one or more additional active agents selected from B2-agonists, PDE IV inhibitors, and corticosteroids. 
Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu prema zahtjevu 11 ili 12, pri čemu se spomenuta primjena dalje sastoji od davanja djelotvorne količine jedne ili više dodatnih aktivnih tvari odabranih iz B2 agonista, inhibitora PDE IV i kortikosteroida.
Machine (1) according to the claim 6, characterized by the fact that said protection element (24) comprises at least a second edge arranged substantially in the proximity of said first edge (17a). 
Uređaj (1) sukladno zahtjevu 6, naznačen time što zaštitni element (24) obuhvaća barem drugi rub organiziran u osnovi u blizini prvog ruba (174).
Medicaments for administration by inhalation desirably have a controlled particle size. 
Poželjno je da lijekovi za primjenu inhalacijom imaju nadziranu veličinu čestica.
Preparation of the salts of the invention 
Datum podnošenja europske prijave patenta:
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) at least one compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants, especially rust diseases on soybean plants. 
Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I) pri čemu je R1 difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; te (B) spoj fluopiram.
The pharmaceutical composition as claimed in any of the preceding claims, wherein the flurbiprofen or pharmaceutically acceptable salts and an a-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist are combined together with at least one pharmaceutically acceptable carrier or excipient. 
Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time što se flurbiprofen ili farmaceutski prihvatljivu sol flurbiprofena i agonistom a-2 adrenergičkog receptora, odnosno agonist gama- aminobutanske kiseline nalaze zajedno u kombinaciji s barem jednim farmaceutski prihvatljivim nosačem ili ekscipientom.
The anti-CD40 antibody or antigen-binding fragment of claim 1 or the use of claim 2, wherein said anti-CD40 antibody or antigen-binding fragment thereof is selected from the group consisting of: 
Monoklonalno antitijelo prema zahtjevu 1, gdje je navedeno antitijelo monoklonalno antitijelo odabrano iz grupe koja se sastoji od:
N -Hydroxypyridine-2-sulfonamide (32) 
(32) Datum podnošenja prve prijave:
The method of any one of embodiments 150 to 222, wherein the mature type I elastase is a mature human type I elastase. 
(b) zreli tip I elastaze je zreli humani tip I elastaze, koji opcionalno sadrži sekvencu aminokiseline koja ima:
is selected from the group consisting of hydrogen, C1-C3 alkyl, C3-C6 cylcoalkyl, C4-C5 alkylcycloalkyl, wherein C1-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy or C1-6 alkoxy; 
X=CHN, NO; R, je izabran iz grupe koja se sastoji od vodika, C,3 alkil, Css cikloalkil, Cy s alkilcikloalkil, gdje je Ci13 alkil izborno supstituiran sa 1 do 3 supstituenta nezavisno izabrana od halogena, hidroksi ili C,.galkoksi;
The treatment agent for use according to any one of claims 5 to 8, wherein the neuropathic pain is fibromyalgia, postherpetic pain, diabetic neuropathy, post-spinal cord injury pain, postapoplectic pain, chronic pain, complex regional pain syndrome, backache for which NSAIDs are insufficiently effective, sciatica, pelvic pain, trigeminal neuralgia, osteoarthritis pain for which NSAIDs are insufficiently effective, deafferentation pain syndrome, pain due to myositis, pain due to fasciitis, and pain due to seronegative arthritis. 
Sredstvo za liječenje namijenjeno uporabi u skladu s patentnim zahtjevom 5 do 8, naznačen time, da je neuropatska bol fibromijalgija, postherpetička bol, dijabetička neuropatija, bol nakon ozljeda leđne moždine, postapopleptična bol, kronična bol, sindrom kompleksnih regionalnih bolova, bol u leđima za koje nesteroidni protuupalni lijekovi (NSAID) nisu dovoljno učinkoviti, išijas, bol u zdjelici, trigeminalna neuralgija, artritična bol za koju nesteroidni protuupalni lijekovi nisu dovoljno učinkoviti, sindrom deaferentacije boli, bol zbog miozitisa, bol zbog fascitisa i bol zbog seronegativnog artritisa
A suspension as in any of claims 1 to 11, wherein the low molecular weight charged polymer is sodium carboxymethylcellulose having a degree of substitution of at least 0.5 up to 0.9. 
Suspenzija prema bilo kojem od zahtjeva 1 do 12, naznačena time, da se kod napunjenog polimera male molekularne mase radi o natrijevoj karboksimetilcelulozi koja ima stupanj supstitucije od najmanje 0,5 pa najviše do 0,9.
A pharmaceutical composition according to claim 10 comprising at least one additional binding molecule that has rabies virus neutralizing activity and binds to a different, non-competing epitope of the rabies virus. A pharmaceutical composition according to claim 11, characterized in that the additional binding molecule comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 273 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 275. 
prvu molekulu za vezanje koja neutralizira virus bjesnoće koja je sposobna vezati se na epitop koji sadrži aminokiseline 226-231 G proteina virusa bjesnoće, te navedeno antitijelo koje neutralizira virus bjesnoće sadrži: varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 273, i varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 275, i drugu molekulu za vezanje koja neutralizira virus bjesnoće koja je sposobna vezati se na epitop smješten u antigenom mjestu III koja sadrži aminokiseline 330-338 G proteina virusa bjesnoće.
A shoe according to claim 1 or 2, wherein said base cushioning elements have the form of internally-hollow capsules (20, 62). 
Obuća sukladno zahtjevu 1 ili 2, pri čemu bazni elementi za ublažavanje imaju isti geometrijski oblik i različite veličine.
Tightening clamp as claimed in any one of the preceding claims, wherein said fixed abutment element consists of prongs of a fork (14) projecting from the fastening arm (3). 
Stezaljka za pričvršćivanje prema bilo kojem od prethodnih patentnih zahtjeva naznačena time da se navedeni čvrsti element za podupiranje sastoji od viličastih zubaca (14) koji izlaze iz stežućeg dijela (3).
7a-Methyl-19-nor-D-homotestosterone is disclosed as a synthetic intermediate in WO 85/05361. 
7a-Metil-19-nor-D-homotestosteron otkriven je kao sintetski međuprodukt u dokumentu WO 85/05361.
The pharmaceutical composition for oral administration according to claim 9, wherein the hydrogel-forming polymer is polyethylene oxide. 
Tableta za oralnu primjenu prema zahtjevu 11, gdje je hidrogel-formirajući polimer polietilen oksid.
When the synthesis is effected by solid phase synthesis, the built-up peptide is then removed from the resin in accordance with methods known in the art, e.g. with acetic acid; trifluoracetic acid; acetic acid-trifluoroethanol-dichloromethane; hexafluoroisopropanol in dichloromethane. 
Kada se sinteza provodi kao sinteza u krutoj fazi, izgrađeni peptid se zatim ukloni sa smole u skladu sa postupcima poznatim u struci, na primjer s octenom kiselinom; trifluorooctenom kiselinom; octena kiselina-trifluoroetanol- diklorometanom; heksafluoroizopropanolom u diklorometanu.
The pharmaceutical composition of any of claims 1-5, wherein the composition exhibits an in vitro dissolution profile such that after 2 hours, from about 0% to about 30% by weight of tapentadol is released, after 4 hours, from about 5% to about 22% by weight of tapentadol is released, after 6 hours, from about 15% to about 30% by weight of tapentadol is released, and after 8 hours more than about 40% by weight of tapentadol is released; when measured using USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37 °C. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1-5, gdje pripravak pokazuje in vitro disolucijski profil takav da nakon 2 sata, otpušta se od oko 0% do oko 30% po masi tapentadola, nakon 4 sata, otpušta se od oko 5% do oko 22% po masi tapentadola, nakon 6 sati, otpušta se oko 15% do oko 30% po masi tapentadola, te nakon 8 sati se otpušta više od oko 40% po masi tapentadola; mjereno USP Basket postupkom pri 75 rpm u 900 mL 0.1 N HCI pri 37 *C.
According to another embodiment the liquid treatment composition comprises the acid in an amount from 0.1 to 100 wt.-%, based on the total weight of the liquid treatment composition, preferably in an amount from 1 to 80 wt.-%, more preferably in an amount from 5 to 60 wt.-%, and most preferably in an amount from 10 to 50 wt.-%. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da tekući pripravak za obradu sadrži kiselinu u količini od 0.1 do 100 mas. %, na temelju ukupne mase tekućeg pripravka za obradu, poželjno u količini od 1 do 80 mas. %, poželjnije u količini od 5 do 60 mas. %, te najpoželjnije u količini od 10 do 50 mas. %.
a.vii.) diafiltrating the mixture from step a.vi) 
vii.) dijafiltracija i ultrafiltracija mješavine iz koraka a.vi).
The method according to claim 1, further comprising the step of isolating the polypeptide of interest from the CHO cells. 
Postupak za dobivanje polipeptida od interesa naznačen time da sadrži korak uzgoja CHO stanica prema zahtjevu
For example, the antibody may comprise a heavy chain wherein CDR-H1 has the sequence given in SEQ ID NO:5 and CDR-H2 has the sequence given in SEQ ID NO:6. 
Neutralizirajuće antitijelo koje posjeduje specifičnost za humani IL-6 i ima teški lanac koji sadrži sekvencu gH13 datu u SEQ ID NO: 11 ilaki lanac koji sadrži sekvencu GL10 datu u SEQ ID NO: 13.
An odour-absorbing composition comprising a mixture of a-, B-, and Y-cyclodextrins, wherein the amount of one of said a-, B-, and Y-cyclodextrins is equal to or higher than the total amount of the other two cyclodextrins. 
Sastav koji apsorbira neugodne mirise, naznačen time, da obuhvaća mješavinu a-, B- i Y-ciklodekstrina, pri čemu je količina jednih od navedenih a-, B- i Y-ciklodekstrina, jednaka ukupnoj količini ili je veća od ukupne količine od preostalih dviju vrsta ciklodekstrina.
scanning and storing image data (18a; 20a; 34) from a light sensor (24; 58) receiving the light from the container and at intervals as a function of apparent rotation of the container, 
(a) skeniranju i spremanju podataka (184; 20a; 34) iz osjetila svjetla (24; 58), koje prima svjetlo sa spremnika, u intervalima koji su funkcija prividnog zakretanja spremnika,
Method 1—Supercritical Fluid Chromatography Mass Spectrum (SFC-MS) 
Kromatografija superkritičnim fluidom/spektometrija masa (SFC-MS)
The method according to claim 16, wherein the block has been made of concrete or a cured artificial stone. The method for manufacturing a sheath section for a container according to claim 16, wherein the block is provided in a substantially tubular shape. The method according to claim 12, wherein the surface conditioning treatment comprises a bush hammering, a chiselling, a pointing and/or a flame chipping. 
Proces prema zahtjevu 10, pri čemu je blok napravljen od betona ili stvrdnutog vještačkog kamena, i/ili pri čemu je process usmjeren na proizvodnju omotača (26) za spremnik (12), i pri čemu je blok, pripremljen u koraku (1), u obliku cijevi. Proces prema jednom od zahtjeva 6 do 11, pri čemu obrada površine obuhvata rezbarenje, klesanje, brušenje i/ili paljenje.
According to European patent specification No. 
Sukladno europskoj patentnoj specifikaciji br.
Item-16) Device according to item 13 wherein the dry powder inhaler apparatus further comprises: a. an integrated mouthpiece cover positioned within the inhaler body, the integrated mouthpiece cover having a loading arm and a dose plate transfer arm, and wherein the integrated mouthpiece cover is moveable between a closed position, in which the dose plate is in the loading position, and an open position, in which the dose plate is in the delivery position and the dosing recess is in the air flow pathway. 
Točka-16) Uređaj prema točki 13 pri čemu uređaj za inhaliranje sa suhim prahom dodatno uključuje: a. integriranu masku za usta postavljenu unutar tijela inhalatora, maska za usta ima ruku za punjenje i ruku za prijenos pločice za doziranje, i pri čemu se integrirana maska za usta može pomicati između zatvorenog položaja, u kojem je pločica za doziranje u položaju za punjenje, i otvorenog položaja, u kojem je pločica za doziranje u položaju za dostavu i utor za doziranje je na putu toka zraka.
The method of claim 9, wherein the first nuclease agent or the second nuclease agent is the ZFN, and the first nuclease recognition site or the second nuclease recognition site comprises any one of SEQ ID NOS: 9-12. 
Postupak prema patentnom zahtjevu 8, naznačen time što je prvo sredstvo nukleaze, drugo sredstvo nukleaze, ili treće sredstvo nukleaze Cas protein i vodeća RNK, pri čemu je Cas protein Cas9, i pri čemu vodeća RNK (gRNA) sadrži:
Method according to claim 1 further comprising step C: 
" NH2 o 2. < Metoda u skladu s patentnim zahtjevom 1 nadalje obuhvaća korak C:
The aqueous agrochemical suspension formulation according to claim 6, wherein an amount of the at least one kind of alcohol selected from the group consisting of ethylene glycol, propylene glycol and glycerin is within a range of 2 to 100 parts by weight, an amount of the inorganic thickener is within a range of 2 to 50 parts by weight and an amount of the dispersant is within a range of 2 to 100 parts by weight, as opposed to 100 parts by weight of 2-(2,6-difluorophenyl)-4-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydrooxazole. 
Vodena agrokemijska suspenzija u skladu sa patentnim zahtjevom 1 ili 6, gdje suspenzija je formulacija 1 količina barem jedne vrste alkohola odabrane iz grupe koja se sastoji od etilen glikola, propilen glikola i glicerina je u okviru opsega od 2 do 100 dijelova po masi, količina neorganskog sredstva za zgušnjavanje je u okviru opsega od 2 do 50 dijelova po masi i količina dispergirajućeg sredstva je u okviru opsega od 2 do 100 dijelova po masi, za razliku od 100 dijelova po masi 2-(2,6-difluorofenil)-4-[4-(1,1-dimetiletil)-2-etoksifenil]-4,5-dihidrooksazola.
The compound of Claim 12, where R3 is hydrogen or fluoro; R4 is hydrogen or fluoro; R5 is hydrogen or fluoro; and R6 is hydrogen, fluoro or chloro. 
Spoj u skladu s patentnim zahtjevom 12, naznačen time, da R3 je vodik ili fluoro; R4 je vodik ili fluoro; R5 je vodik ili fluoroo; i R6 je vodik, fluoro ili kloro.
decode the data of the current partition, with the exclusion of the sign, 
- < dekodiranje podataka navedene trenutne particije, s izuzetkom navedenog predznaka,
providing the container (1), 
osiguravanje posude (1), -
The reactions (final volume = 200 µL) were incubated for 30 min at 25 °C and washed on Unifilter-GF/B with water. 
Reakcije (završni volumen = 200 ul) se inkubiraju kroz 30 min na 25 "C i isperu na Unifilteru-GF/B sa vodom.
The method according to claim 1, wherein the ischemia or reperfusion injury is ischemia or reperfusion injury of the brain, heart, lung, or kidney. The method according to claim 1, wherein the pharmaceutical compositions are administered before reperfusion. 
Kombinacija ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 6 naznačena time što je ishemijska i/ili reperfuzijska ozljeda, ishemijska i/ili reperfuzijska ozljeda mozga, srca, pluća, bubrega, poželjno ishemija miokarda, reperfuzijska ozljeda miokarda ili akutni infarkt miokarda.
The apparatus of claim 2 wherein the body defines a plurality of indexing notches configured for engagement with a geneva wheel of said lifter assembly. The apparatus of claim 5 wherein said needle cassette further comprises means for permitting rotation of the body in only one direction. The apparatus of claim 2 wherein said needle cassette includes means cooperating with said computer means to allow detection of at least certain angular positions of the body about said axis of rotation. 
Aparatura u skladu s patentnim zahtjevom 5, naznačen time što navedena kazeta za igle nadalje sadržava sredstvo (209,210, 211, 588, 622) koje dopušta rotiranje tijela samo u jednom smjeru. Aparatura u skladu s patentnim zahtjevom 2, naznačena time što navedena kazeta za igle uključuje sredstva (589) koja rade zajednički s navedenim računalnim sredstvima, kako bi se na taj način omogućilo detektiranje barem nekih kutnih položaja tijela oko navedene osi rotacije.
The polypeptide of any of claims 1 to 7 the nucleic acid of claim 8 or the pharmaceutical composition of any of claims 11 to 13 for use as a medicament, particularly as a vaccine. 
Polipeptid sukladno bilo kojem patentnom od zahtjeva 1 do 4, naznačen time, što je nukleinska kiselina sukladno zahtjevu 5 ili farmaceutski pripravak sukladno bilo kojem patentnom od zahtjeva 8 do13. naznačen time, da se upotrebljava kao lijek, posebno kao cjepivo.
C1-8 alkyl (said C1-8 alkyl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of the following (i) to (v); halogen, 
(c) Cg alkil (navedeni C,_g alkil može biti supstituiran s 1, 2 ili 3 supstituenta, koje se bira iz skupine koju čine sljedeći (1) do (v);
applying a solution comprising poly (ethylene glycol) having a concentration of about 10% by weight and glycine having a concentration of about 4% to 8% by weight to the cation exchange chromatography material, thereby separating the antibody of the IgG class in monomeric form from the antibody in aggregate form and obtaining the antibody in monomeric form. 
- proizvodnja protutijela IgG-razreda u monomernom obliku primjenom otopine koja sadrži poli(etilenglikol) i sorbitol na kromatografski materijal, te time desorbiranje / eluiranje protutijela IeG- razreda u monomernom obliku iz kromatografskog materijala, pri čemu poli(etilenglikol) ima koncentraciju od 10 masenih % i sorbitol ima koncentraciju od 5 masenih % do 20 masenih %.
The composition of claim 1, wherein the anti-mold agent is selected from the group consisting of potassium sorbate, sorbic acid, benzoic acid, p-oxybenzoic acid. 
Postupak prema zahtjevu 2, naznačen time da je sredstvo protiv plijesni odabrano iz skupine koju čine kalijev sorbat, sorbinsku kiselinu, benzojeva kiselina, p-oksibenzojeva kiselina.
(e1) A is a poly (diethylene glycol)adipate having a theoretical molecular weight of from 500 to 3,500 Daltons; 
[image] pri čemu A je poliester koji ima teorijsku molekulsku masu od 500 do 3500 Daltona;
A method of delivering a blend of graded aggregate and a stabilising agent to a reinstatement work site, the method including steps of: preparing a premixed blend of the graded aggregate and placing the same into a plurality of torpedoes or tubes, 
Postupak za isporuku mješavine klasificiranog agregata i sredstva za stabiliziranje do mjesta izvođenja rekonstrukcije naznačen time da sadrži korake: a) pripremu prethodno izmiješane mješavine klasificiranog agregata i postavljanja iste u mnoštvo torpeda ili cijevi (10) postavljenih unutar kućišta (70) b) dodavanje sredstva za stabiliziranje u agregat